ESMO 2026: Dr. Xiaofu Zhu on Breast Cancer Takeaways from Early to Advanced Disease
Dr. Xiaofu Zhu, medical oncologist at the Cross Cancer Institute in Edmonton, shares key takeaways from NATALEE, NSABP B-42 and FOURLIGHT-1, discussing adjuvant ribociclib, extended endocrine therapy and emerging CDK4 inhibition—and what these findings could mean for clinical practice.